Phase 1/2 study of BLU-701, a highly selective EGFR inhibitor, in patients with EGFR-mutant non-small cell lung cancer Meeting Abstract
| Authors: | Spira, A.; Spigel, D. R.; Camidge, R.; de Langen, A. J.; Kim, T. M.; Goto, K.; Elamin, Y.; Shum, E.; Reckamp, K. L.; Rotow, J.; Goldberg, S.; Gadgeel, S.; Leal, T. A.; Albayya, F.; Fitzpatrick, S.; Louie-Gao, M.; Parepally, J.; Zalutskaya, A.; Yu, H. |
| Abstract Title: | Phase 1/2 study of BLU-701, a highly selective EGFR inhibitor, in patients with EGFR-mutant non-small cell lung cancer |
| Meeting Title: | 2022 World Conference on Lung Cancer |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 17 |
| Issue: | 9 Suppl. |
| Meeting Dates: | 2022 Aug 6-9 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-09-01 |
| Start Page: | S406 |
| Language: | English |
| DOI: | 10.1016/j.jtho.2022.07.701 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: EP08.02-019 -- Located within section named "EP08.02 Metastatic Non-Small Cell Lung Cancer - Molecular Targeted Treatments" -- Accession Number: 159037947 -- Entry Date: In Process -- Revision Date: 20220913 -- Publication Type: Article -- Supplement Title: 2022 Supplement -- Journal Subset: Biomedical; Blind Peer Reviewed; Peer Reviewed; USA -- NLM UID: 101274235. -- Source: Cinahl |
